Fig. 2.

Antiviral activity over time, as assessed by a HIV-1 RNA* and b CD4+ percentage during pregnancy and postpartum. HIV-1 human immunodeficiency virus-1, qd once daily, ARV antiretroviral. *For each time point, percentages may not total 100% due to rounding. ^†The baseline visit occurred at 18–26 weeks gestation; per the inclusion criteria, eligible subjects were receiving rilpivirine 25 mg qd as part of their ARV regimen at the time of study entry